{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:17:59Z","timestamp":1778069879216,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.clml.2026.02.011","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T20:40:24Z","timestamp":1772484024000},"page":"e661-e668.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Systemic Inflammatory and Autoimmune Diseases on Outcomes in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1758-2321","authenticated-orcid":false,"given":"Selin","family":"Cebeci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5713-5830","authenticated-orcid":false,"given":"Emir","family":"Serra\u00e7","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9496-5353","authenticated-orcid":false,"given":"Tu\u011frul","family":"Elverdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ay\u015fe","family":"Saliho\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhlis Cem","family":"Ar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015eeniz","family":"\u00d6ng\u00f6ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafer","family":"Ba\u015flar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9568-0894","authenticated-orcid":false,"given":"Ahmet Emre","family":"E\u015fkazan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9936","key":"10.1016\/j.clml.2026.02.011_bib0001","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(13)61901-7","article-title":"Myelodysplastic syndromes","volume":"383","author":"Ad\u00e8s","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clml.2026.02.011_bib0002","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.leukres.2013.01.004","article-title":"Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine","volume":"37","author":"Ad\u00e8s","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2026.02.011_bib0003","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.yjmcc.2021.07.004","article-title":"Clonal hematopoiesis of indeterminate potential (CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease","volume":"161","author":"Marnell","year":"2021","journal-title":"J Mol Cell Cardiol"},{"issue":"469","key":"10.1016\/j.clml.2026.02.011_bib0004","first-page":"820","article-title":"\u2018[b]Syndromes[\/b] my\u00e9lodysplasiques et auto-immunit\u00e9","volume":"11","author":"Stalder","year":"2015","journal-title":"Rev Med Suisse"},{"issue":"3","key":"10.1016\/j.clml.2026.02.011_bib0005","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0925-5710(97)00042-X","article-title":"Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients","volume":"66","author":"Okamoto","year":"1997","journal-title":"Int J Hematol"},{"issue":"12","key":"10.1016\/j.clml.2026.02.011_bib0006","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2026.02.011_bib0007","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/ajh.24396","article-title":"Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management","volume":"91","author":"Patnaik","year":"2016","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.clml.2026.02.011_bib0008","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1182\/blood-2018-06-857102","article-title":"Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials","volume":"133","author":"Platzbecker","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2026.02.011_bib0009","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/rheumatology\/keh136","article-title":"Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study","volume":"43","author":"Giannouli","year":"2004","journal-title":"Rheumatology"},{"key":"10.1016\/j.clml.2026.02.011_bib0010","first-page":"33","article-title":"Autoimmune diseases: recent insights on epidemiology, pathogenesis, and prevalence rate","volume":"1133","author":"Nautiyal","year":"2024","journal-title":"Stud Comput Intell"},{"issue":"2","key":"10.1016\/j.clml.2026.02.011_bib0011","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/rheumatology\/kev294","article-title":"Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study","volume":"55","author":"Mekinian","year":"2015","journal-title":"Rheumatology (United Kingdom)"},{"issue":"8","key":"10.1016\/j.clml.2026.02.011_bib0012","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.leukres.2013.04.007","article-title":"Myelodysplastic syndromes and autoimmune diseases\u2014case series and review of literature","volume":"37","author":"Al Ustwani","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2026.02.011_bib0013","doi-asserted-by":"crossref","first-page":"108168","DOI":"10.1016\/j.leukres.2026.108168","article-title":"Impact of autoimmune diseases or inflammatory manifestations on response and outcome in high-risk myelodysplastic syndromes and chronic myelomonocytic leukemia","author":"Sammut","year":"2026","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.clml.2026.02.011_bib0014","doi-asserted-by":"crossref","first-page":"E280","DOI":"10.1002\/ajh.24333","article-title":"Autoimmune diseases and myelodysplastic syndromes","volume":"91","author":"Komrokji","year":"2016","journal-title":"Am J Hematol"},{"issue":"13","key":"10.1016\/j.clml.2026.02.011_bib0015","first-page":"e3091","article-title":"Certain autoimmune manifestations are associated with distinctive karyotypes and outcomes in patients with myelodysplastic syndrome: a retrospective cohort study","volume":"95","author":"Lee","year":"2016","journal-title":"Medicine (United States)"},{"issue":"8","key":"10.1016\/j.clml.2026.02.011_bib0016","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/rheumatology\/ken162","article-title":"Behcet\u2019s disease associated with bone marrow failure in Korean patients: clinical characteristics and the association of intestinal ulceration and trisomy 8","volume":"47","author":"Ahn","year":"2008","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.clml.2026.02.011_bib0017","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/ejh.13174","article-title":"Inflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective case-control study","volume":"102","author":"Wesner","year":"2019","journal-title":"Eur J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.02.011_bib0018","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2024-204167","article-title":"IDH-1 somatic mutations are more commonly observed among patients with concomitant myelodysplastic syndromes (MDS) and autoimmune rheumatoid diseases (AIRD)","volume":"144","author":"Komrokji","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2026.02.011_bib0019","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00277-018-3472-9","article-title":"Autoimmune manifestations associated with myelodysplastic syndromes","volume":"97","author":"Grignano","year":"2018","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.clml.2026.02.011_bib0020","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1468-3083.2007.02520.x","article-title":"Cutaneous manifestations in relation to immunologic parameters in a cohort of primary myelodysplastic syndrome patients","volume":"22","author":"Dalamaga","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.clml.2026.02.011_bib0021","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/ajh.27156","article-title":"VEXAS syndrome: clinical, hematologic features and a practical approach to diagnosis and management","volume":"99","author":"Koster","year":"2024","journal-title":"Am J Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:38:55Z","timestamp":1778067535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026000613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2152265026000613"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.02.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Systemic Inflammatory and Autoimmune Diseases on Outcomes in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}